Stefan Suciu

1986–2024 年に発表

98
論文数
20,835
被引用数
78
h 指数
98
i10 指数

被引用数

Stefan Suciu の年別被引用数1948 年: 被引用 2 件1986 年: 被引用 2 件1987 年: 被引用 2 件1988 年: 被引用 2 件1989 年: 被引用 5 件1990 年: 被引用 5 件1991 年: 被引用 8 件1992 年: 被引用 1 件1993 年: 被引用 14 件1994 年: 被引用 11 件1995 年: 被引用 18 件1996 年: 被引用 18 件1997 年: 被引用 35 件1998 年: 被引用 37 件1999 年: 被引用 48 件2000 年: 被引用 81 件2001 年: 被引用 57 件2002 年: 被引用 85 件2003 年: 被引用 101 件2004 年: 被引用 63 件2005 年: 被引用 86 件2006 年: 被引用 91 件2007 年: 被引用 81 件2008 年: 被引用 95 件2009 年: 被引用 120 件2010 年: 被引用 97 件2011 年: 被引用 132 件2012 年: 被引用 105 件2013 年: 被引用 167 件2014 年: 被引用 98 件2015 年: 被引用 128 件2016 年: 被引用 171 件2017 年: 被引用 176 件2018 年: 被引用 214 件2019 年: 被引用 769 件2020 年: 被引用 701 件2021 年: 被引用 723 件2022 年: 被引用 520 件2023 年: 被引用 409 件2024 年: 被引用 540 件2025 年: 被引用 238 件2026 年: 被引用 1 件1949〜1985 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,084 件、この内訳の 24.3%ドイツ: 引用元論文 672 件、この内訳の 7.8%イタリア: 引用元論文 573 件、この内訳の 6.7%フランス: 引用元論文 535 件、この内訳の 6.2%中国: 引用元論文 533 件、この内訳の 6.2%イギリス: 引用元論文 522 件、この内訳の 6.1%オランダ: 引用元論文 496 件、この内訳の 5.8%オーストラリア: 引用元論文 382 件、この内訳の 4.4%カナダ: 引用元論文 242 件、この内訳の 2.8%スイス: 引用元論文 241 件、この内訳の 2.8%スペイン: 引用元論文 239 件、この内訳の 2.8%ベルギー: 引用元論文 235 件、この内訳の 2.7%
0%24.3%その他 21.4%

分野

  • Medicine78.1%
  • Biochemistry, Genetics and Molecular Biology11.2%
  • Immunology and Microbiology8.6%
  • Engineering0.5%
  • Neuroscience0.3%
  • Materials Science0.3%
  • その他1%

トピック

  • Cancer Immunotherapy and Biomarkers10.5%
  • Acute Myeloid Leukemia Research6.8%
  • Immunotherapy and Immune Responses6.6%
  • Cutaneous Melanoma Detection and Management5.2%
  • Acute Lymphoblastic Leukemia research5.1%
  • CAR-T cell therapy research4.8%
  • その他61%

共著者

全論文

検索で開く
  1. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,853

  2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci ほか 32 名 - The Lancet Oncology 2021 被引用: 389

  3. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2020 被引用: 436

  4. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 1,313

  5. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - NEJM Evidence 2022 被引用: 150

  6. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 1,255

  7. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 286

  8. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Caroline Robert - Journal of Clinical Oncology 2020 被引用: 281

  9. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

    著者: , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2019 被引用: 180

  10. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 348

  11. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 551

  12. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mario Mandalà - European Journal of Cancer 2022 被引用: 49

  13. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2024 被引用: 81

  14. Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 475

  15. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ulrich Dührsen, Frédéric Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin Huls, Jürgen Finke, Nicolaas Petrus Michael Schaap, Andrius Zucenka, Stephan Metzelder, Edgar Jost, Zinaida Perić, Fabio Forghieri, Bernadino Allione, Maurizio Martelli, Anna Paola Iori, Sebastian Wittnebel, Andrea Mengarelli, Annalisa Imovilli, Attilio Olivieri, Bernard José Marie De Prijck, Marjolein W.M. van der Poel, Christian Junghanß, Helmut Rainer Salih, Agostino Tafuri, José Eduardo Guimarães, Maurizio Musso, Paolo De Fabritiis, Patrice Chevallier, Dominik Luc Selleslag, Nicola Cascavilla, Zwi Berneman, Aurélie Jaspers, Eliana Zuffa, Gaëtan Vanstraelen, Giuseppe Visani, Maria Louisa Henriëtte Cuijpers, Ann De Becker, Anna Maria Mianulli, Björn Hackanson, Georgi Georgiev Mihaylov, Giovanni Martinelli, Stefania Paolini, Pier Luigi Zinzani, Martin Henkes, Haifa Kathrin Al-Ali, Paul La Rosée, Anna Chierichini, Laura Cudillo, Giorgina Specchia, Njetočka Gredelj Šimec, Silvana Franca Capalbo, Giuseppina Spinosa, Stefano Molica, Susan Dorothé de Jonge-Peeters - The Lancet Haematology 2023 被引用: 37

  16. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michal Kiciński, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Thierry Lesimple, Michele Maio, Gerald P. Linette, Laurent Mortier, Inge Marie Svane, Jacob Schachter, Michael P. Brown, Peter Hersey, Catherine Barrow, Ragini R. Kudchadkar, Caroline Dutriaux, Xinni Song, Pietro Quaglino, Paola Queirolo, Friedegund Meier, Daniil Stroyakovskiy, B. Guillot, Pablo L. Ortiz‐Romero, Lars Bastholt, Claus Garbe, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Carmen Loquai, Frank Meiß, Vanna Chiarion‐Sileni, Gil Bar‐Sela, Bernard M. Fitzharris, Philippe Saïag, Jean‐Philippe Arnault, Jan‐Christoph Simon, Rosalie Stephens, Jean‐François Baurain, Célèste Lebbé, P. Combemale, Reinhard Dummer, Axel Hauschild, Phillip Parente, Naoya Yamazaki, Mohammed Milhem, M.‐T. Leccia, L. Geoffrois, Lutz Kretschmer, Elaine Dunwoodie, John Walker, Michal Lotem, Daniel Hendler, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Marcin Dzienis, Geke A.P. Hospers, Marco Siano, Jessica C. Hassel, Philippa Corrie, Maria-Jose Passos, Max Levin, Christoph Höeller, L. Machet, Sigrun Hallmeyer, Ashita Waterston, V. Descamps, Felix Kiecker, Maureen J.B. Aarts, Henrik Schmidt ほか 34 名 - The Lancet Oncology 2021 被引用: 72

  17. Sex Is an Independent Prognostic Indicator for Survival and Relapse/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials

    著者: , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 191

  18. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2017 被引用: 167

  19. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

    著者: , , , , , , , , , , , , , , , - Annals of Oncology 2014 被引用: 147

  20. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2015 被引用: 103

  21. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

    著者: , , , , , , , , , , , , , , , - The Lancet 2008 被引用: 642

  22. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2013 被引用: 152

  23. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert - European Journal of Cancer 2021 被引用: 28

  24. Expression of MAGE genes in primary and metastatic cutaneous melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - International Journal of Cancer 1995 被引用: 285